Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) SVP Elizabeth L. Hougen sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 29th. The shares were sold at an average price of $53.02, for a total transaction of $318,120.00. Following the completion of the sale, the senior vice president now owns 16,392 shares of the company’s stock, valued at $869,103.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) traded up $1.44 during midday trading on Friday, hitting $56.93. 1,149,432 shares of the stock were exchanged, compared to its average volume of 1,468,307. Ionis Pharmaceuticals, Inc. has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a current ratio of 6.25, a quick ratio of 6.21 and a debt-to-equity ratio of 1.50. The firm has a market capitalization of $7,080.00, a PE ratio of 352.87 and a beta of 2.89.
Several hedge funds and other institutional investors have recently bought and sold shares of IONS. Vanguard Group Inc. lifted its position in shares of Ionis Pharmaceuticals by 4.4% during the second quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock worth $501,332,000 after purchasing an additional 417,364 shares in the last quarter. American Century Companies Inc. lifted its position in shares of Ionis Pharmaceuticals by 33.0% during the third quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock worth $58,027,000 after purchasing an additional 284,266 shares in the last quarter. First Trust Advisors LP lifted its position in shares of Ionis Pharmaceuticals by 40.2% during the third quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock worth $49,805,000 after purchasing an additional 281,733 shares in the last quarter. BlackRock Inc. lifted its position in shares of Ionis Pharmaceuticals by 4.0% during the second quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock worth $347,135,000 after purchasing an additional 264,179 shares in the last quarter. Finally, Smith Asset Management Group LP acquired a new position in shares of Ionis Pharmaceuticals during the second quarter worth $11,394,000. 91.58% of the stock is currently owned by institutional investors and hedge funds.
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.